Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer

Alexander S. Parker, Michael G. Heckman, Yuri Sheinin, Kevin J. Wu, Tracy W. Hilton, Nancy N. Diehl, Thomas M. Pisansky, Steven E. Schild, Eugene D. Kwon, Steven J. Buskirk

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Purpose: The ability to predict which men will experience biochemical recurrence (BCR) after salvage radiation therapy (SRT) for recurrent prostate cancer (PCa) remains less than optimal. Related to this, novel targets for adjuvant therapies are also lacking. Here, we evaluate the association of B7-H3 expression in primary PCa tumors and BCR after SRT. Methods and Materials: We identified 148 patients who received SRT between July 1987 and July 2003. Expression of B7-H3 in primary PCa tumors was detected using a monoclonal antibody. The staining levels were quantified via visual assessment and categorized as weak, moderate, or marked. Relative risks (RRs) and 95% confidence intervals (CIs) from Cox proportional hazards models were used to examine the association between B7-H3 staining and BCR. Results: With a median follow-up of 6.2 years (minimum, 0.6; maximum, 14.7), 78 patients (53%) experienced BCR. In single-variable analysis, there was evidence of an increased risk of BCR for patients with moderate (RR, 2.25; 95% CI, 1.24-4.09, p = 0.008) and marked (RR, 4.40, 95% CI, 2.29-8.43, p < 0.001) B7-H3 staining compared with weak staining. This evidence remained, albeit weaker, after adjustment for additional clinicopathologic covariates (RR, 1.82, p = 0.068 [moderate vs. weak]; RR, 2.87, p = 0.003 [marked vs. weak]). Conclusion: This is the first report that higher tumor B7-H3 staining in primary PCa tumors is associated with increased risk of BCR after SRT. Future studies involving larger numbers of patients are required to validate these results and also to explore possible means of targeting B7-H3 in an adjuvant setting.

Original languageEnglish (US)
Pages (from-to)1343-1349
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume79
Issue number5
DOIs
StatePublished - Apr 1 2011

Fingerprint

Salvage Therapy
biomarkers
radiation therapy
Prostatic Neoplasms
Radiotherapy
Biomarkers
staining
cancer
Recurrence
evaluation
Staining and Labeling
tumors
confidence
Confidence Intervals
intervals
Neoplasms
antibodies
Proportional Hazards Models
hazards
therapy

Keywords

  • Biochemical recurrence
  • Prostate cancer
  • Salvage radiation therapy
  • Tumor biomarker

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer. / Parker, Alexander S.; Heckman, Michael G.; Sheinin, Yuri; Wu, Kevin J.; Hilton, Tracy W.; Diehl, Nancy N.; Pisansky, Thomas M.; Schild, Steven E.; Kwon, Eugene D.; Buskirk, Steven J.

In: International Journal of Radiation Oncology Biology Physics, Vol. 79, No. 5, 01.04.2011, p. 1343-1349.

Research output: Contribution to journalArticle

Parker, AS, Heckman, MG, Sheinin, Y, Wu, KJ, Hilton, TW, Diehl, NN, Pisansky, TM, Schild, SE, Kwon, ED & Buskirk, SJ 2011, 'Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer', International Journal of Radiation Oncology Biology Physics, vol. 79, no. 5, pp. 1343-1349. https://doi.org/10.1016/j.ijrobp.2010.01.061
Parker, Alexander S. ; Heckman, Michael G. ; Sheinin, Yuri ; Wu, Kevin J. ; Hilton, Tracy W. ; Diehl, Nancy N. ; Pisansky, Thomas M. ; Schild, Steven E. ; Kwon, Eugene D. ; Buskirk, Steven J. / Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer. In: International Journal of Radiation Oncology Biology Physics. 2011 ; Vol. 79, No. 5. pp. 1343-1349.
@article{d8c0db5dab3443b685f6f616abce79c8,
title = "Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer",
abstract = "Purpose: The ability to predict which men will experience biochemical recurrence (BCR) after salvage radiation therapy (SRT) for recurrent prostate cancer (PCa) remains less than optimal. Related to this, novel targets for adjuvant therapies are also lacking. Here, we evaluate the association of B7-H3 expression in primary PCa tumors and BCR after SRT. Methods and Materials: We identified 148 patients who received SRT between July 1987 and July 2003. Expression of B7-H3 in primary PCa tumors was detected using a monoclonal antibody. The staining levels were quantified via visual assessment and categorized as weak, moderate, or marked. Relative risks (RRs) and 95{\%} confidence intervals (CIs) from Cox proportional hazards models were used to examine the association between B7-H3 staining and BCR. Results: With a median follow-up of 6.2 years (minimum, 0.6; maximum, 14.7), 78 patients (53{\%}) experienced BCR. In single-variable analysis, there was evidence of an increased risk of BCR for patients with moderate (RR, 2.25; 95{\%} CI, 1.24-4.09, p = 0.008) and marked (RR, 4.40, 95{\%} CI, 2.29-8.43, p < 0.001) B7-H3 staining compared with weak staining. This evidence remained, albeit weaker, after adjustment for additional clinicopathologic covariates (RR, 1.82, p = 0.068 [moderate vs. weak]; RR, 2.87, p = 0.003 [marked vs. weak]). Conclusion: This is the first report that higher tumor B7-H3 staining in primary PCa tumors is associated with increased risk of BCR after SRT. Future studies involving larger numbers of patients are required to validate these results and also to explore possible means of targeting B7-H3 in an adjuvant setting.",
keywords = "Biochemical recurrence, Prostate cancer, Salvage radiation therapy, Tumor biomarker",
author = "Parker, {Alexander S.} and Heckman, {Michael G.} and Yuri Sheinin and Wu, {Kevin J.} and Hilton, {Tracy W.} and Diehl, {Nancy N.} and Pisansky, {Thomas M.} and Schild, {Steven E.} and Kwon, {Eugene D.} and Buskirk, {Steven J.}",
year = "2011",
month = "4",
day = "1",
doi = "10.1016/j.ijrobp.2010.01.061",
language = "English (US)",
volume = "79",
pages = "1343--1349",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer

AU - Parker, Alexander S.

AU - Heckman, Michael G.

AU - Sheinin, Yuri

AU - Wu, Kevin J.

AU - Hilton, Tracy W.

AU - Diehl, Nancy N.

AU - Pisansky, Thomas M.

AU - Schild, Steven E.

AU - Kwon, Eugene D.

AU - Buskirk, Steven J.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Purpose: The ability to predict which men will experience biochemical recurrence (BCR) after salvage radiation therapy (SRT) for recurrent prostate cancer (PCa) remains less than optimal. Related to this, novel targets for adjuvant therapies are also lacking. Here, we evaluate the association of B7-H3 expression in primary PCa tumors and BCR after SRT. Methods and Materials: We identified 148 patients who received SRT between July 1987 and July 2003. Expression of B7-H3 in primary PCa tumors was detected using a monoclonal antibody. The staining levels were quantified via visual assessment and categorized as weak, moderate, or marked. Relative risks (RRs) and 95% confidence intervals (CIs) from Cox proportional hazards models were used to examine the association between B7-H3 staining and BCR. Results: With a median follow-up of 6.2 years (minimum, 0.6; maximum, 14.7), 78 patients (53%) experienced BCR. In single-variable analysis, there was evidence of an increased risk of BCR for patients with moderate (RR, 2.25; 95% CI, 1.24-4.09, p = 0.008) and marked (RR, 4.40, 95% CI, 2.29-8.43, p < 0.001) B7-H3 staining compared with weak staining. This evidence remained, albeit weaker, after adjustment for additional clinicopathologic covariates (RR, 1.82, p = 0.068 [moderate vs. weak]; RR, 2.87, p = 0.003 [marked vs. weak]). Conclusion: This is the first report that higher tumor B7-H3 staining in primary PCa tumors is associated with increased risk of BCR after SRT. Future studies involving larger numbers of patients are required to validate these results and also to explore possible means of targeting B7-H3 in an adjuvant setting.

AB - Purpose: The ability to predict which men will experience biochemical recurrence (BCR) after salvage radiation therapy (SRT) for recurrent prostate cancer (PCa) remains less than optimal. Related to this, novel targets for adjuvant therapies are also lacking. Here, we evaluate the association of B7-H3 expression in primary PCa tumors and BCR after SRT. Methods and Materials: We identified 148 patients who received SRT between July 1987 and July 2003. Expression of B7-H3 in primary PCa tumors was detected using a monoclonal antibody. The staining levels were quantified via visual assessment and categorized as weak, moderate, or marked. Relative risks (RRs) and 95% confidence intervals (CIs) from Cox proportional hazards models were used to examine the association between B7-H3 staining and BCR. Results: With a median follow-up of 6.2 years (minimum, 0.6; maximum, 14.7), 78 patients (53%) experienced BCR. In single-variable analysis, there was evidence of an increased risk of BCR for patients with moderate (RR, 2.25; 95% CI, 1.24-4.09, p = 0.008) and marked (RR, 4.40, 95% CI, 2.29-8.43, p < 0.001) B7-H3 staining compared with weak staining. This evidence remained, albeit weaker, after adjustment for additional clinicopathologic covariates (RR, 1.82, p = 0.068 [moderate vs. weak]; RR, 2.87, p = 0.003 [marked vs. weak]). Conclusion: This is the first report that higher tumor B7-H3 staining in primary PCa tumors is associated with increased risk of BCR after SRT. Future studies involving larger numbers of patients are required to validate these results and also to explore possible means of targeting B7-H3 in an adjuvant setting.

KW - Biochemical recurrence

KW - Prostate cancer

KW - Salvage radiation therapy

KW - Tumor biomarker

UR - http://www.scopus.com/inward/record.url?scp=79952703623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952703623&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2010.01.061

DO - 10.1016/j.ijrobp.2010.01.061

M3 - Article

C2 - 20598810

AN - SCOPUS:79952703623

VL - 79

SP - 1343

EP - 1349

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -